Navigation Links
HeartWare to Present at the Canaccord Genuity 31st Annual Growth Conference
Date:8/8/2011

FRAMINGHAM, Mass. and SYDNEY, Aug. 8, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Canaccord Genuity 31st Annual Growth Conference at 9:00 a.m. U.S. Eastern Time on Thursday, August 11, 2011.  The conference is being held August 9-11, 2011 at The InterContinental Hotel in Boston.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time for 90 days.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
2. HeartWare to Report Financial Results for Second Quarter of 2011
3. HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
4. HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
5. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
6. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
7. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
8. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
9. HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference
10. HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
11. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... YORK , March 27, 2017 FinancialBuzz.com News ... According to a new ... North America , grew 34 percent to $6.7 billion and ... rate of (CAGR) over the next five years, from $6.7 billion in ... of Americans that will be able to purchase cannabis without a doctor,s ...
(Date:3/27/2017)... 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus ... Invictus MD is pleased to announce it has received ... on the TSX Venture Exchange.  Receiving ... year of significant achievements for Invictus-MD. Some of which ... at AB Laboratories Inc. ("AB Labs"), a Licensed Producer ...
(Date:3/27/2017)... -- The staggering cost of cancer treatment means only ... the latest treatment options against cancer. Even among the ... inadequate or no health insurance and are oftentimes saddled ... modern cancer treatment is almost non-existent for cancer patients ... mission statements of pharmaceutical and biotech companies often quote ...
Breaking Medicine Technology:
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in shock ... the best days I’ve had in a long time,” she said. , She thinks the ... of money that I never thought I would have to help my students.” , The ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... pleased to announce the launch of a months-long rebranding effort. This includes the ... , “Through focus group discussions and market research, we learned that a simple, ...
(Date:3/27/2017)... ... ... The homeowner improvement and repair market is expected to reach $317 billion in ... is also on the rise. Per a 2017 report, 13% of all households undertook ... use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not only slash ...
(Date:3/25/2017)... ... ... Norland at Swissray is pleased to announce the release of the ELITE DXA, ... has an active scan window, which is more than double that of existing bone densitometers. ... could not undergo an accurate total body bone density or body composition study. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
Breaking Medicine News(10 mins):